Page 1

Company Announcement 25 November 2021 PACIFIC EDGE PACIFIC EDGE RESULTS FOR SIX MONTHS ENDED 30 SEPTEMBER 2021 Pacific Edge reports continued strong revenue growth despite continuing impact of Covid - 19 Unaudited results for the six months ended 30 September 2021 ( 1H22 ) Summary of performance for the period ( % changes compared to prior comparative period ( pcp ) ) : • Total revenue increased 66 % to $ 6.7m • Operating revenue from test sales increased 62 % to $ 5.4m • • • • • Total Laboratory Throughput increased 62 % to 11,136 tests Commercial Test volumes increased 64 % to 9,192 tests Cash Receipts from Customers increased 110 % to $ 5.4m Total operating expenses increased 41 % on pcp to $ 15.7m Net Loss After Tax increased 27 % to $ 9.0m Net cash , cash equivalents and short - term deposits were $ 91.6m ( which excludes the $ 23.5m raised in the Retail Offer completed in October 2021 ) Growth in the US sales force from 16 to 28 ( + 75 % ) and the addition of two new sales territories Publication of clinical evidence key to supporting use of multiple Cxbladder products and Pacific Edge's Patient In - Home Sampling System ( PIHSS ) Conducted successful $ 103.5m capital raise and dual listed on ASX Well positioned to capitalise on commercial milestones as Covid - 19 restrictions ease , with a strong balance sheet and scaled up operations in the U.S. Cancer diagnostics business , Pacific Edge Limited ( NZX / ASX : PEB ) has reported continuing growth for the six months ended 30 September 2021 ( 1H22 ) , with key performance metrics significantly ahead of the same time last year , driven by reimbursement milestones , increasing insurance coverage and adoption by urologists and healthcare organisations . CEO of Pacific Edge , David Darling , commented : “ The momentum seen in 2H21 has continued with growth in test volumes , sales and cash receipts . This is particularly pleasing given the resurgence in Covid - 19 restrictions due to the spread of the Delta variant , which further restricted access to clinics and urologists for both patients and for our sales people in both the U.S. and New Zealand . As Covid - 19 restrictions are lifted and access improves , we expect to see a positive impact on our business . " With a restructured balance sheet and significant cash resources now in hand , we continue to focus on scaling up our commercial operations to accelerate our growth in the U.S. and other targeted markets . We continue to make good progress as we position our Cxbladder suite of tests as the diagnostic product of choice for urologists and patients . The clinical evidence supporting the outperformance of our products , growing endorsement by key opinion leaders and our first mover advantage all serve to provide a strong competitive advantage for our business . " In particular , the recent clinical papers published in the leading Journal of Urology , highlight a pivotal shift in clinical utility from , firstly , an increase in clinical resolution from the combined use of multiple Cxbladder tests for each patient presenting with haematuria and , secondly , the gain in clinical utility from Pacific Edge's PIHSS for